Immunomodulation of murine experimental SLE-like disease by interferon-γ

H. Amital, Y. Levi, M. Blank, V. Barak, P. Langevitz, A. Afek, F. Nicoletti, J. Kopolovic, B. Gilburd, P. L. Meroni, Y. Shoenfeld

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The objective of this study was to assess the impact of murine recombinant IFN-γ and anti-IFN-γ monoclonal antibody on the BALB/c mice experimental model of lupus. BALB/c female mice were immunized with a human anti-DNA antibody that carries the 16/6 idiotype. These mice were divided into several therapeutic groups according to different treatment strategies; injection with mouse recombinant IFN-γ, anti-IFN-γ mAb, phosphate-buffered saline (PBS), irrelevant mouse IgG and control groups that were neither treated nor immunized with the human anti-DNA antibody. The administration of IFN-γ intensified the degree of clinical, histological and serological parameters in this model of BALB/c murine lupus. This immunomanipulation decreased the mice longevity. All the laboratory parameters reflected acceleration of the disease in the IFN-γ treated group as an elevated sedimentation rare, decreased white blood cell count and the development of massive proteinuria. One month after the boost injection, all the mice that were immunized with the anti-DNA antibody, developed high titers of autoantibodies; however, following an additional month, their levels declined in the IFN-γ treated group. These findings were in concordance with an increased glomerular deposition of immune complexes in the IFN-γ treated mice. IFN-γ upregulated the levels of IL-4 and increased the number of IL-4 and IL-6 secreting splenocytes. In conclusion IFN-γ, administration can aggravate the clinical and laboratory outcome of 16/6 id induced lupus in BALB/c mice.

Original languageEnglish
Pages (from-to)445-454
Number of pages10
JournalLupus
Volume7
Issue number7
DOIs
Publication statusPublished - 1998

Fingerprint

Immunomodulation
Interferons
Antinuclear Antibodies
Interleukin-4
Injections
Antigen-Antibody Complex
Leukocyte Count
Proteinuria
Autoantibodies
Interleukin-6
Theoretical Models
Immunoglobulin G
Phosphates
Monoclonal Antibodies
Control Groups

Keywords

  • Cytokines
  • IFN-γ
  • Systemic lupus erythematosus
  • Th1 cells
  • Th2 cells

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Amital, H., Levi, Y., Blank, M., Barak, V., Langevitz, P., Afek, A., ... Shoenfeld, Y. (1998). Immunomodulation of murine experimental SLE-like disease by interferon-γ. Lupus, 7(7), 445-454. https://doi.org/10.1191/096120398678920406

Immunomodulation of murine experimental SLE-like disease by interferon-γ. / Amital, H.; Levi, Y.; Blank, M.; Barak, V.; Langevitz, P.; Afek, A.; Nicoletti, F.; Kopolovic, J.; Gilburd, B.; Meroni, P. L.; Shoenfeld, Y.

In: Lupus, Vol. 7, No. 7, 1998, p. 445-454.

Research output: Contribution to journalArticle

Amital, H, Levi, Y, Blank, M, Barak, V, Langevitz, P, Afek, A, Nicoletti, F, Kopolovic, J, Gilburd, B, Meroni, PL & Shoenfeld, Y 1998, 'Immunomodulation of murine experimental SLE-like disease by interferon-γ', Lupus, vol. 7, no. 7, pp. 445-454. https://doi.org/10.1191/096120398678920406
Amital H, Levi Y, Blank M, Barak V, Langevitz P, Afek A et al. Immunomodulation of murine experimental SLE-like disease by interferon-γ. Lupus. 1998;7(7):445-454. https://doi.org/10.1191/096120398678920406
Amital, H. ; Levi, Y. ; Blank, M. ; Barak, V. ; Langevitz, P. ; Afek, A. ; Nicoletti, F. ; Kopolovic, J. ; Gilburd, B. ; Meroni, P. L. ; Shoenfeld, Y. / Immunomodulation of murine experimental SLE-like disease by interferon-γ. In: Lupus. 1998 ; Vol. 7, No. 7. pp. 445-454.
@article{0f43859eb16344bf8fcef112bcdd615a,
title = "Immunomodulation of murine experimental SLE-like disease by interferon-γ",
abstract = "The objective of this study was to assess the impact of murine recombinant IFN-γ and anti-IFN-γ monoclonal antibody on the BALB/c mice experimental model of lupus. BALB/c female mice were immunized with a human anti-DNA antibody that carries the 16/6 idiotype. These mice were divided into several therapeutic groups according to different treatment strategies; injection with mouse recombinant IFN-γ, anti-IFN-γ mAb, phosphate-buffered saline (PBS), irrelevant mouse IgG and control groups that were neither treated nor immunized with the human anti-DNA antibody. The administration of IFN-γ intensified the degree of clinical, histological and serological parameters in this model of BALB/c murine lupus. This immunomanipulation decreased the mice longevity. All the laboratory parameters reflected acceleration of the disease in the IFN-γ treated group as an elevated sedimentation rare, decreased white blood cell count and the development of massive proteinuria. One month after the boost injection, all the mice that were immunized with the anti-DNA antibody, developed high titers of autoantibodies; however, following an additional month, their levels declined in the IFN-γ treated group. These findings were in concordance with an increased glomerular deposition of immune complexes in the IFN-γ treated mice. IFN-γ upregulated the levels of IL-4 and increased the number of IL-4 and IL-6 secreting splenocytes. In conclusion IFN-γ, administration can aggravate the clinical and laboratory outcome of 16/6 id induced lupus in BALB/c mice.",
keywords = "Cytokines, IFN-γ, Systemic lupus erythematosus, Th1 cells, Th2 cells",
author = "H. Amital and Y. Levi and M. Blank and V. Barak and P. Langevitz and A. Afek and F. Nicoletti and J. Kopolovic and B. Gilburd and Meroni, {P. L.} and Y. Shoenfeld",
year = "1998",
doi = "10.1191/096120398678920406",
language = "English",
volume = "7",
pages = "445--454",
journal = "Lupus",
issn = "0961-2033",
publisher = "SAGE Publications Ltd",
number = "7",

}

TY - JOUR

T1 - Immunomodulation of murine experimental SLE-like disease by interferon-γ

AU - Amital, H.

AU - Levi, Y.

AU - Blank, M.

AU - Barak, V.

AU - Langevitz, P.

AU - Afek, A.

AU - Nicoletti, F.

AU - Kopolovic, J.

AU - Gilburd, B.

AU - Meroni, P. L.

AU - Shoenfeld, Y.

PY - 1998

Y1 - 1998

N2 - The objective of this study was to assess the impact of murine recombinant IFN-γ and anti-IFN-γ monoclonal antibody on the BALB/c mice experimental model of lupus. BALB/c female mice were immunized with a human anti-DNA antibody that carries the 16/6 idiotype. These mice were divided into several therapeutic groups according to different treatment strategies; injection with mouse recombinant IFN-γ, anti-IFN-γ mAb, phosphate-buffered saline (PBS), irrelevant mouse IgG and control groups that were neither treated nor immunized with the human anti-DNA antibody. The administration of IFN-γ intensified the degree of clinical, histological and serological parameters in this model of BALB/c murine lupus. This immunomanipulation decreased the mice longevity. All the laboratory parameters reflected acceleration of the disease in the IFN-γ treated group as an elevated sedimentation rare, decreased white blood cell count and the development of massive proteinuria. One month after the boost injection, all the mice that were immunized with the anti-DNA antibody, developed high titers of autoantibodies; however, following an additional month, their levels declined in the IFN-γ treated group. These findings were in concordance with an increased glomerular deposition of immune complexes in the IFN-γ treated mice. IFN-γ upregulated the levels of IL-4 and increased the number of IL-4 and IL-6 secreting splenocytes. In conclusion IFN-γ, administration can aggravate the clinical and laboratory outcome of 16/6 id induced lupus in BALB/c mice.

AB - The objective of this study was to assess the impact of murine recombinant IFN-γ and anti-IFN-γ monoclonal antibody on the BALB/c mice experimental model of lupus. BALB/c female mice were immunized with a human anti-DNA antibody that carries the 16/6 idiotype. These mice were divided into several therapeutic groups according to different treatment strategies; injection with mouse recombinant IFN-γ, anti-IFN-γ mAb, phosphate-buffered saline (PBS), irrelevant mouse IgG and control groups that were neither treated nor immunized with the human anti-DNA antibody. The administration of IFN-γ intensified the degree of clinical, histological and serological parameters in this model of BALB/c murine lupus. This immunomanipulation decreased the mice longevity. All the laboratory parameters reflected acceleration of the disease in the IFN-γ treated group as an elevated sedimentation rare, decreased white blood cell count and the development of massive proteinuria. One month after the boost injection, all the mice that were immunized with the anti-DNA antibody, developed high titers of autoantibodies; however, following an additional month, their levels declined in the IFN-γ treated group. These findings were in concordance with an increased glomerular deposition of immune complexes in the IFN-γ treated mice. IFN-γ upregulated the levels of IL-4 and increased the number of IL-4 and IL-6 secreting splenocytes. In conclusion IFN-γ, administration can aggravate the clinical and laboratory outcome of 16/6 id induced lupus in BALB/c mice.

KW - Cytokines

KW - IFN-γ

KW - Systemic lupus erythematosus

KW - Th1 cells

KW - Th2 cells

UR - http://www.scopus.com/inward/record.url?scp=7844221012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7844221012&partnerID=8YFLogxK

U2 - 10.1191/096120398678920406

DO - 10.1191/096120398678920406

M3 - Article

C2 - 9796846

AN - SCOPUS:7844221012

VL - 7

SP - 445

EP - 454

JO - Lupus

JF - Lupus

SN - 0961-2033

IS - 7

ER -